COMPANY PROFILE

Renibus Therapeutics

Explore full profile

Operates in the healthcare industry focusing on the pharmaceutical business

Southlake, United StatesFounded 2015Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Renibus Therapeutics

Renibus Therapeutics is a biopharmaceutical company focused on developing innovative therapies for chronic kidney disease (CKD) and postoperative complications. Operating in the healthcare and pharmaceutical markets, Renibus serves patients undergoing cardiothoracic surgeries and those suffering from CKD. The company's business model revolves around research and development, progressing through clinical trials to bring new treatments to market. Renibus makes money by advancing its drug candidates through various phases of clinical trials, securing regulatory approvals, and eventually commercializing these therapies. The company is currently working on RBT 1, aimed at reducing postoperative complications in cardiothoracic surgery patients, and RBT 2, which targets CKD progression by restoring cellular balance and reducing inflammation. Both products are in different stages of clinical trials, with RBT 1 in Phase II and RBT 2 expected to start Phase I/II studies soon.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Southlake, United States
Employees: 31
Open positions: None listed
Dealroom signal: 61.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Sep 2023	$25M	$235M	Undisclosed	↗
SERIES BOther financing	Jul 2023	$47M	$188M	Undisclosed	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Renibus Therapeutics website traffic

Latest recorded traffic for Renibus Therapeutics is 4.5K monthly website visits, up 25% over the last three months. Renibus Therapeutics's team declined 3.1% over the past year.

Latest monthly visits4.5K 3-month web change+25% 1-year team growth-3.1%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
LTLiMM TherapeuticsDeveloper of antibiotics and immunomodulators, harnessing harnessing the molecular cross-talk between neuronal and innate lymphoid cells	Paris, France	Closed
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational
FAFabentechSpecializes in the development and production of emergency treatments to combat the risks of bioterrorism and emerging infectious diseases that are priorities for public health	Lyon, France	Operational